We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Brentuximab Vedotin‐Nivolumab alone and then with Rituximab‐Cyclophosphamide‐Doxorubicin‐Prednisone as Frontline Therapy of Primary Mediastinal Large B‐cell Lymphoma.
- Authors
Steiner, R. E.; Strati, P.; Flowers, C. R.; Neelapu, S. S.; Green, M.; Nastoupil, L. J.; Hagemeister, F. B.; Feng, L.; Ahmed, S.; Nair, R.; Fayad, L.; Lee, H. J.; Rodriguez, M. A.; Westin, J. R.
- Abstract
Although most PMBL patients can be cured with frontline chemoimmunotherapy (CIT) with or without radiotherapy (XRT), the outcome of patients having rr-PMBCL is generally unfavorable. B Introduction: b Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a rare, aggressive subtype of diffuse large B-cell lymphoma and affects primarily young adults. The trial CheckMate-436 treated relapsed/refractory (rr) PMBCL patients with nivolumab (antibody that binds to PD-1) and brentuximab vedotin ((BV) anti-CD30 antibody-drug conjugate), who showed an overall response rate (ORR) of 73% and complete response rate (CRR) of 43% (Zinzani et al.
- Subjects
DIFFUSE large B-cell lymphomas; LYMPHOMAS
- Publication
Hematological Oncology, 2023, Vol 41, p167
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3163_T03